Amanda Ast, APRN
Family · Wichita, KSNPI 1255834735
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,911 of the $9,002 with a category attached, or 76.8%. 35 manufacturers reported payments, led by Insulet Corporation at 24.2% of the total. 2025 is the largest year on record at $3,543, 5.6 times the $634 reported in 2021. Among family clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 471 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$2K
- Lilly USA, LLC$1K
- Dexcom, Inc.$744
- Abbott$725
- Senseonics, Incorporated$640
- Novo Nordisk$639
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$6407%
- Travel & lodging$1,40216%
- Food & beverage$6,91177%
- Education$481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 71 | $2,179 |
| Lilly USA, LLC | 61 | $1,088 |
| Dexcom, Inc. | 57 | $744 |
| Abbott | 66 | $725 |
| Senseonics, Incorporated | 2 | $640 |
| Novo Nordisk | 43 | $639 |
| Sanofi-aventis U.S. LLC | 20 | $529 |
| Bayer | 27 | $417 |
| Corcept Therapeutics | 26 | $300 |
| Xeris Pharmaceuticals, Inc. | 17 | $238 |
| Amgen | 9 | $167 |
| Boehringer Ingelheim | 9 | $162 |
| Recordati_rare_diseases_inc. | 6 | $149 |
| AstraZeneca | 9 | $145 |
| AbbVie | 9 | $135 |
| Novartis | 5 | $109 |
| Ascensia Diabetes Care US Inc. | 4 | $85 |
| BETA Bionics, Inc. | 6 | $70 |
| Sequel Med Tech, LLC | 3 | $58 |
| Radius Health, Inc. | 2 | $57 |
| Currax Pharmaceuticals LLC | 3 | $57 |
| Nevro Corp. | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $29 |
| Averitas Pharma Inc. | 1 | $29 |
| Medtronic | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Chiesi USA, Inc. | 1 | $22 |
| Recor Medical Inc | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Embecta Corp. | 1 | $15 |
| Merck | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$1,486
- Eversense$640
- SOLIQUA 100/33$103
- TOUJEO$101
How this compares
$9,002 in reported general payments places this provider in the 95th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 285 | $316,286 |
| JardianceEmpagliflozin | 180 | $129,457 |
| MounjaroTirzepatide | 102 | $111,382 |
| Tresiba Flextouch U-200Insulin Degludec | 79 | $78,347 |
| TrulicityDulaglutide | 51 | $51,908 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 69 | $46,245 |
| Tresiba Flextouch U-100Insulin Degludec | 101 | $44,701 |
| FarxigaDapagliflozin Propanediol | 43 | $40,880 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 42 | $37,584 |
| JanuviaSitagliptin Phosphate | 40 | $28,837 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $27,455 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 32 | $24,766 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $15,215 |
| Novolog FlexpenInsulin Aspart | 78 | $14,729 |
| Humalog Kwikpen U-100Insulin Lispro | 53 | $10,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $639 | $320,256299 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,088 | $166,079167 claims |
| Boehringer IngelheimJardiance | $162 | $129,457180 claims |
| MerckJanuvia, Janumet Xr | $13 | $44,05261 claims |
| AstraZenecaFarxiga | $145 | $40,88043 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $529 | $37,58442 claims |
| AbbVieSynthroid | $135 | $2,22135 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $1,622212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,579 family providers in Kansas.
Other family in Wichita
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Mary GonzalesWichita$87K
- Mary GarciaWichita$24K
- Jennifer NeelWichita$15K
- Jennifer MartinWichita$8K
- Lauren CoteWichita$7K
- Mimi TranWichita$6K
- Kara NabboutWichita$6K
- Zohra HussainiKansas City$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.